|Bid||1,511.00 x 0|
|Ask||1,512.00 x 0|
|Day's Range||1,503.00 - 1,526.50|
|52 Week Range||1,356.00 - 2,056.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||18.66|
|Earnings Date||Apr 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1,968.50|
NORTHBROOK, Ill. , April 3, 2019 /PRNewswire/ -- Astellas is pleased to announce two recent senior-level promotions and one new hire within its Medical and Development (M&D) organization. Steven Benner ...
- Study results will be presented at American Association for Cancer Research Annual Meeting 2019 - TOKYO , April 1, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa ...
BOTHELL, Wash. and TOKYO, March 28, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive topline results from the first cohort of patients in a pivotal phase 2 single-arm clinical trial known as EV-201. The cohort is evaluating enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received previous treatment with both platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor. Enfortumab vedotin is an investigational antibody-drug conjugate (ADC) that targets Nectin-4, a therapeutic target that is highly expressed in multiple solid tumors including urothelial cancers.
- Investigational compound fezolinetant reduced frequency and severity of vasomotor symptoms in postmenopausal women - TOKYO , March 26, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President ...
TOKYO/HONG KONG (Reuters) - Japanese share buybacks have hit a record this fiscal year and are set to maintain the booming growth as cash-rich companies bow to pressure from investors and the government to boost returns and improve governance. In recent weeks, SoftBank Group Corp, Sony, Itochu Corp and other companies have announced plans to buy back shares worth more than 1.3 trillion yen, bringing the total value of buybacks flagged since April 1 to over 6.5 trillion yen ($58.92 billion). Investors have long criticised Japanese companies for hoarding cash rather than investing it or returning it to shareholders, pushing down their returns on equity (ROE), a measure of the amount of profit a company generates from the money invested in it.
Data to be presented at the 2019 Genitourinary Cancers Symposium NEW YORK and TOKYO , Feb. 11, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji ...
Japan's Nikkei rose for a third day on Wednesday as signs of progress in Sino-U.S. trade talks boosted confidence, offsetting weakness in chip-related stocks which underperformed on a Goldman Sachs report which forecast a tough year ahead. The United States and China have extended trade talks in Beijing for an unscheduled third day as the world's two largest economies look to resolve their bitter trade dispute.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (PFE) today announced that the Phase 3 ARCHES trial evaluating XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) met its primary endpoint, significantly improving radiographic progression-free survival (rPFS) versus ADT alone. The preliminary safety analysis of the ARCHES trial appears consistent with the safety profile of XTANDI in previous clinical trials in castration-resistant prostate cancer (CRPC). “While XTANDI is currently approved for both metastatic and non-metastatic CRPC, there still remains a need for more treatment options for men with metastatic hormone-sensitive prostate cancer,” said Mace Rothenberg, M.D., Chief Development Officer, Oncology, Pfizer Global Product Development.
TOKYO and NORTHBROOK, Ill., Dec. 14, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it exercised, and closed on its exclusive option to acquire Potenza Therapeutics, Inc. ("Potenza") on December 13, 2018, U.S. Eastern Time. This acquisition marks the successful outcome of a collaboration agreement entered into in 2015 to build a portfolio of novel immuno-oncology (IO) therapies. The clinical IO therapies developed through this collaboration may also provide a platform for IO combinations with Astellas' existing non-IO programs for life cycle management and future novel IO combinations. "This transaction underscores Astellas' commitment to innovation and scientific partnerships to advance our creation of value for patients," said Kenji Yasukawa, Ph.D., President and CEO, Astellas.
TOKYO , Dec. 10, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced that XOSPATA ® (generic name: gilteritinib) is now ...
TOKYO , Dec. 3, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced updated results from a Phase 1 study of gilteritinib ...
- FLT3 mutation-positive AML is a life-threatening disease with significant unmet medical needs - - XOSPATA is the first and only FLT3 inhibitor approved by the FDA for patients with relapsed or refractory ...
The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation. The treatment, Xospata, was approved for patients with acute myeloid leukemia (AML) with a FLT3 mutation, whose cancer has relapsed or proved treatment-resistant. The drug, taken once a day in tablet form, will have a wholesale acquisition cost of $22,500 for a month's supply, Astellas said.
TOKYO and NORTHBROOK, Ill., Nov. 20, 2018 /PRNewswire/ -- Astellas Pharma Inc. (4503.T) (President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced the launch of the Astellas Global Health Foundation (AGHF), a new international philanthropic organization dedicated to improving access to health in underserved global communities. Key areas of focus for the AGHF initially will be neglected tropical and communicable diseases, children's health and mental health in low-income communities and low-and middle-income countries where Astellas, a company dedicated to improving the health of people around the world, does not have a commercial presence.
Many of the world's top drugmakers are not doing enough to provide medicines to poor countries, leaving big gaps in access to treatments in crucial disease areas, including cancer, according to a new report on Tuesday. The non-profit Access to Medicine Foundation (AMF) found companies overall were doing more than in the past to reach under-served populations, for example by setting lower prices for some drugs and improving transparency surrounding patents. What is more, research into urgently needed medicines for the developing world now relies on just a handful of companies, creating a fragile ecosystem where cutbacks by one player could have a significant impact on future supplies.
- Abstracts include updated results from Phase 1 study of gilteritinib in patients with newly diagnosed AML - TOKYO , Nov. 19, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: ...
Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs 14.7 months for men who received placebo plus ADT(1) ...